GSK (NYSE:GSK) Cut to “Buy” at Wall Street Zen

Wall Street Zen downgraded shares of GSK (NYSE:GSK) from a strong-buy rating to a buy rating in a research note published on Saturday morning.

A number of other research firms have also recently commented on GSK. TD Cowen reissued a “hold” rating on shares of GSK in a research note on Monday, February 9th. HSBC reaffirmed a “reduce” rating on shares of GSK in a research note on Wednesday, December 10th. Morgan Stanley reiterated an “underweight” rating on shares of GSK in a research note on Wednesday, January 14th. Bank of America raised GSK from an “underperform” rating to a “neutral” rating in a report on Tuesday, November 25th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of GSK in a research note on Friday, January 16th. Two analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $44.13.

GSK Price Performance

GSK stock opened at $55.51 on Friday. The stock has a market capitalization of $113.13 billion, a P/E ratio of 15.00, a P/E/G ratio of 3.30 and a beta of 0.44. The company’s fifty day moving average price is $54.04 and its 200 day moving average price is $47.98. The company has a debt-to-equity ratio of 0.92, a quick ratio of 0.54 and a current ratio of 0.82. GSK has a 1 year low of $32.38 and a 1 year high of $61.69.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 9th. Investors of record on Friday, February 20th will be given a dividend of $0.4856 per share. The ex-dividend date is Friday, February 20th. This is a boost from GSK’s previous quarterly dividend of $0.42. This represents a $1.94 dividend on an annualized basis and a yield of 3.5%. GSK’s dividend payout ratio (DPR) is presently 51.62%.

Insider Transactions at GSK

In other GSK news, major shareholder Plc Gsk acquired 1,470,000 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average price of $19.00 per share, with a total value of $27,930,000.00. Following the purchase, the insider owned 18,245,691 shares in the company, valued at approximately $346,668,129. The trade was a 8.76% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 10.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Fisher Asset Management LLC grew its position in shares of GSK by 4.4% in the second quarter. Fisher Asset Management LLC now owns 31,338,405 shares of the pharmaceutical company’s stock valued at $1,203,395,000 after purchasing an additional 1,306,590 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S lifted its position in GSK by 2,032.8% during the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 854,331 shares of the pharmaceutical company’s stock worth $41,896,000 after buying an additional 814,275 shares in the last quarter. PFA Pension Forsikringsaktieselskab purchased a new position in GSK during the fourth quarter worth approximately $6,385,000. Align Financial LLC acquired a new position in GSK during the fourth quarter worth $5,628,000. Finally, Leuthold Group LLC acquired a new position in GSK during the fourth quarter worth $4,922,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK agreed to license worldwide rights to linerixibat to Alfasigma, handing development, manufacturing and commercialization to the partner and receiving an upfront payment that improves near‑term cash flow and removes late‑stage development burden. GSK licenses liver disease drug to Italy’s Alfasigma (Reuters)
• Positive Sentiment: Deal economics: GSK will receive $300m upfront, up to $100m on U.S. approval and roughly $290m in regulatory/sales milestones plus tiered double‑digit royalties — providing both immediate proceeds and upside tied to commercial success. GSK Sells Rights to Drug Candidate to Alfasigma for Up to $690 Million (Yahoo)
• Neutral Sentiment: Market commentary highlights GSK’s broader operational themes (manufacturing strength and portfolio repositioning) that could support longer‑term earnings stability but are less likely to move the stock materially in the near term. Manufacturing Prowess Emerges as Key GSK Investment Theme
• Neutral Sentiment: Analyst and media pieces weighing valuation after a strong share run‑up frame the stock as cheaper on fundamentals but raise questions about remaining upside — useful context but not an immediate catalyst. Is It Too Late to Buy GSK After a 46% Share Price Jump? (247WallSt)
• Negative Sentiment: Some analysts still hold cautious views: GSK recently had a consensus “Reduce” rating from analysts, which could cap near‑term upside if coverage drives selling pressure despite the deal. GSK Receives Consensus Recommendation of “Reduce” (American Banking News)

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.